English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Hengrui Received Approval for Clinical Trial in China for Autoimmune Drug

Jul. 13, 2016

Shanghai Hengrui Pharmaceutical Co., Ltd. has received a clinical trial application approval from the CFDA of its SHR-1314, a self-developed IL-17A, a humanized monoclonal antibody drug, mainly for the treatment of psoriasis and other suitable autoimmune disorders include Crohn’s disease, multiple sclerosis (MS), asthma and rheumatoid arthritis (RA).